May 24, 2012
Bloomberg NewsThe U.S. Senate voted to let regulators collect on a $6.4 billion fee agreement struck with Indianapolis-based Eli Lilly and
Co., Medtronic Inc. and other companies to fund reviews of new drugs and medical devices through 2017.
More
May 17, 2012
Bloomberg NewsRaising good cholesterol, a goal pursued by Eli Lilly and Co. as the next milestone in cardiac care, may not cut heart-attack
risk, says a study that challenges the development of drugs that may someday generate billions of dollars in sales.
More
May 17, 2012
Bloomberg NewsEli Lilly and other big pharmaceutical companies are creating thousands of research jobs overseas as countries led by Singapore,
Ireland and South Africa boost incentives.
More
May 17, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. and London-based AstraZeneca Plc aren't expected to have an easier time gaining more
of the market for blood thinners dominated by Bristol-Myers Squibb Co.’s Plavix after the drug loses U.S. patent protection
Thursday.
More
May 7, 2012
Associated PressA second experimental cholesterol medicine in a once-promising class of drugs meant to replace blockbusters such as Lipitor
has failed in testing, casting doubt on whether any of the drugs will ever make it to pharmacies. Eli Lilly is developing
a similar drug.
More
May 7, 2012
J.K. WallFor more than a year, Eli Lilly and Co. has been viewed by investors as a laggard stock with one, slim shot at producing a
huge jackpot: its experimental Alzheimer’s drug. But now company leaders are trying to direct investor attention toward
the drugmaker’s diabetes portfolio.
More
May 3, 2012
IBJ Staff and Associated Press, Bloomberg NewsAuthorities have arrested two Cuban brothers in the 2010 theft of about $80 million in Eli Lilly and Co. prescription drugs
from a Connecticut warehouse, a robbery described as one of the biggest pharmaceutical heists in history, the U.S. attorney's
office said Thursday.
More
May 3, 2012
Bloomberg NewsMore than 20 compounds that Eli Lilly and Co., Pfizer Inc. and AstraZeneca Plc failed to turn into drugs will be tested by
U.S.-sponsored scientists in a $20 million program to see if they’ll work against ailments they weren’t aimed
at previously.
More
May 2, 2012
Bloomberg NewsThe market for testosterone-replacement treatments is growing, but health experts say overuse of the drugs can be dangerous.
More
April 30, 2012
IBJ Staff and Bloomberg NewsA Vivus Inc. pill that is supposed to provide erections within 15 minutes, about half the time or less than Eli Lilly and
Co.'s Cialis or Pfizer Inc.’s Viagra, has received U.S. regulatory approval.
More
April 16, 2012
J.K. WallThe proposal garnered support from the owners of 62 percent of Eli Lilly's outstanding shares. To pass, the proposal needed
approval from the owners of 80 percent of Lilly’s shares.
More
April 16, 2012
Associated PressEndocyte Inc. stock more than doubled in premarket trading after the company entered into an agreement to develop its ovarian
cancer treatment with pharmaceutical giant Merck & Co.
More
April 9, 2012
J.K. WallEli Lilly and Co.’s newest drug is a boon for Alzheimer’s research but is likely to bring the Indianapolis drugmaker
less than $100 million in annual sales—at least initially, according to one of the few analysts to make a forecast.
More
April 2, 2012
Bloomberg NewsExpress Scripts Inc.’s $29.1 billion bid for rival drug benefit manager Medco Health Solutions Inc. won unconditional
approval from U.S. antitrust regulators, clearing the way to create the biggest manager of prescription-drug benefits for
corporate and government clients.
More
March 23, 2012
IBJ Staff and Associated Press, Associated PressEuropean regulators have approved an expanded use for the diabetes treatment Byetta, developed by Eli Lilly and Co. and Amylin
Pharmaceuticals Inc. The FDA approved the same expanded use last fall.
More
March 20, 2012
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will introduce “over a dozen” new products in China in the next five years,
focusing on “unmet needs” such as cancer and diabetes, CEO John Lechleiter said this week.
More
March 19, 2012
IBJ Staff and Bloomberg NewsExpress Scripts Inc.’s bid to acquire Medco Health Solutions Inc. and create the largest U.S. pharmacy-benefits manager
may be delayed by a lawsuit being considered by five states.
More
March 13, 2012
J.K. WallEndocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after
the European Commission granted it orphan drug status.
More
March 10, 2012
Bloomberg NewsTwo pharmacy groups opposing Express Scripts Inc.’s proposed acquisition of Medco Health Solutions Inc. said they were
asked by the U.S. Federal Trade Commission to suggest ways to revise the $29.1 billion deal so it wouldn’t harm competition.
More
March 5, 2012
J.K. WallEndocyte Inc. can start enrolling patients again in a clinical trial of its experimental cancer drug, the company announced
Monday, clearing away a hurdle to getting the drug approved in Europe.
More
March 1, 2012
Bloomberg NewsDoctors can still get free samples of medicines, but not football tickets or lunch for their spouses, under a revised code
of conduct drafted by a global drug industry trade group that counts Eli Lilly as a member.
More
February 27, 2012
IBJ Staff and Bloomberg NewsEli Lilly and Co. plans to invest about $440 million in a new pharmaceutical plant at an existing company site in County Cork
in southern Ireland. The facility in Kinsale will require as many as 200 skilled employees when fully operational.
More
February 2, 2012
Associated PressFor drugmakers, the golden era of the 1990s and early part of the last decade, when they seemed to effortlessly churn out
new multibillion-dollar pills for the masses along with double-digit quarterly profit increases, is not even in the rearview
mirror any more.
More
January 31, 2012
Bloomberg NewsEli Lilly and Co. is among about a half-dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in
a deal that may value the Turkish drugmaker at $1 billion, sources say.
More
January 29, 2012
Bloomberg NewsAmylin Pharmaceuticals Inc. and Alkermes Plc have gained U.S. clearance for Bydureon, a once-weekly diabetes shot. Eli Lilly
and Co. co-developed the drug, but ended its partnership with Amylin last year.
More
we love that we were right in our predictions for the outcome of Tony's boondoggle. We aren't negative, we are positive that the league that never has will continue to blow chunks and stink up the place
I was initially excited to learn that this wasn't rubber-stamped, but if all that is required is to add some shrubs and some "window dressing" over the first floor of the garage, then I'd call it a waste of everyone's time. It should be noted that the Hearing Examiner is a DMD employee who reports to the same administrator as the DMD staff planner who recommended approval of the garage and whose report said that the requirement for ground-floor retail had been "satisfied". Better luck with appealing the inevitable approval at the MDC, where the commissioners are appointed by the Mayor, City Council, and County Commissioners, thus, presumably not all obligated to facilitate the administration's plans.
Wheat Thins, when paired with chocolate ice cream!
About the same.
New airport, new Lucas Oil Stadium, expanded convention center, $30,000,000 Pacer gift, Stupid City Way Project, Broad Ripple Parking Garage $ Giveaway, Money blown on lethal bike lanes. The list is endless..
We have complete morons in City Government with grafter buddies sitting in the wings also stealing parking meter revenue. Go to www.adavceindiana.com and read about Chicago Parking Meter Corruption.
It's all theft of taxpayer resources and complete lack of financial stewardship and devoid of integrity.
I would just like for basic city services please.